Company Overview and News

 
Minda Global to expand study disciplines, improve intake

2018-02-20 thestar.com.my
KUALA LUMPUR: Private education provider Minda Global Bhd expects to develop new programmes to expand the group's study disciplines and improve student intake growth.

 
Minda Gloal opens at 21.5 sen on Main Market

2018-02-19 thestar.com.my
KUALA LUMPUR: Minda Global Bhd opens at 21.5 sen when it made its debut on the Main Market of Bursa Malaysia on Monday. At 9.05am, it was trading at 20 sen. There were 28,000 shares done at prices ranging from 20 sen to 22 sen. The FBM KLCI was up 4.01 points or 0.22% to 1,842.29. Turnover was 175 million shares valued at RM63.76mil. There were 208 gainers, 32 losers and 153 counters unchanged. Minda Global took over the listing status of Asiamet Education Group Bhd (AEGB) where the last traded price was 22 sen.

 
Minda Global to list on Monday

2018-02-16 thestar.com.my
Minda Global will take over the listing status of Asiamet Education Group Bhd (AEGB), which will be delisted. Under the proposed share exchange, Minda Global shares were issued and allotted to the shareholders of AEGB in exchange for their AEGB shares.

 
Minda Global’s listing deferred

2018-02-15 themalaymailonline
In a filing to Bursa Malaysia today, Asiamet through Maybank Investment Bank said a new date for the listing would be announced later. — Bernama picKUALA LUMPUR, Feb 15 — Asiamet Education Group Bhd has announced that the Main Market listing of Minda Global Bhd, which was scheduled for Feb 15, has been deferred to a later date.

 
SMRT in share placement deals with 4 parties, to raise RM42mil

2017-12-21 thestar.com.my
PETALING JAYA: Technology, education and human resource training provider SMRT Holdings Bhd has entered into four placement agreements with Dayatahan Sdn Bhd, Lembaga Tabung Haji (LTH), Kenanga Private Equity Sdn Bhd and Kenanga Investment Bank Bhd, placing them 210 million consideration shares or a 16.9% stake in Asiamet Education Group Bhd (AEGB).

 
Tabung Haji and Kenanga buy minority stakes in Asiamet

2017-12-21 thestar.com.my
KUALA LUMPUR: Lembaga Tabung Haji and Kenanga Investment Bank Bhd have emerged as minority shareholders in Asiamet Education Group Bhd (AEGB) via a private placement exercise by parent company SMRT Holdings Bhd .

 
KLCI to trade lacklustre on tepid sentiment

2016-12-05 theedgemarkets
KUALA LUMPUR (Dec 6): The FBM KLCI is expected to trade lacklustre today as the broader sentiment at the local market remains tepid.

 
SMRT on path to recovery

2016-11-11 thestar.com.my
Revenue generator: Unknown to many, SMRT’s university, CUCMS, is now one of the main contributors to SMRT’s earnings, and has been recording solid and recurring income over the last two years.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...